Inovio Pharmaceuticals Q2 Earnings Call Highlights

Key Points

• INO-3107’s FDA review is nearing completion, with late-cycle review and pre-licensure inspections finished and the target action date still set for Oct. 30, 2026. The FDA has not yet decided whether the treatment qualifies for accelerated approval, while Inovio expects label discussions to begin in September.
• Inovio is preparing for a potential U.S. launch by selecting Syneos Health as its contract sales organization, developing targeted marketing and patient-support programs, and highlighting INO-3107’s potential advantages over surgery and competing treatments.
• The company ended Q2 with $36.7 million in cash and raised approximately $18.3 million through a July offering. Inovio expects its resources to fund operations into late Q1 2027, including pre-launch spending and a potential INO-3107 launch.

Inovio Pharmaceuticals NASDAQ: INO said the U.S. Food and Drug Administration has completed several key steps in its review of the company’s biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues preparations for a potential commercial launch.

The FDA’s target action date for the application remains Oct. 30, 2026. Chief Executive Officer Dr. Jacqueline Shea said the agency has completed its late-cycle review meeting and all scheduled pre-licensure inspections. Inovio also held a previously requested informal clinical meeting with the FDA in July to present its safety, efficacy and product-differentiation data.

Regulatory Review Nears Final Stages

Chief Medical Officer Dr. Mike Sumner said the completed inspections covered clinical operations, drug manufacturing, in-house drug testing and the company’s delivery-device facility. He said inspectors reported one observation, which Inovio believes it has addressed and is responding to with the FDA.

Sumner said the FDA did not provide a preliminary conclusion during the informal meeting on whether INO-3107 qualifies for accelerated approval, an issue identified in the agency’s December 2025 file-acceptance letter. The agency indicated that its review remains ongoing and that feedback on Inovio’s proposed confirmatory trial design is forthcoming.

Inovio believes INO-3107 meets accelerated-approval criteria because it could offer meaningful therapeutic benefit relative to existing treatments and address a continuing unmet need in RRP. The company cited phase I/II data in which it said most patients experienced a 50% to 100% reduction in surgeries during the first year, with continued improvement in the second year.

Management also highlighted what it views as product advantages over Pepzimos, including that INO-3107 does not require patients to undergo scoping and surgery during its dosing window to maintain minimal residual disease. Sumner said Inovio expects to begin label negotiations in September and, if the product is approved, expects seven years of orphan-drug market exclusivity based on its delivery method and mechanism of action.

Commercial Infrastructure Takes Shape

Chief Commercial Officer Steve Egge said Inovio has moved into the implementation phase of launch planning. The company has selected Syneos Health as its contract sales organization for a potential U.S. commercialization effort and plans targeted marketing efforts and a patient-support hub.

Egge said early uptake of Pepzimos, with approximately 200 patients reportedly treated, validates demand for alternatives to surgery. He characterized that figure as low-single-digit penetration of the prevalent RRP patient population, leaving most patients open to new treatment options.

Inovio said INO-3107’s potential commercial differentiation includes the absence of specialized ultra-cold-chain handling requirements, which management said could provide greater flexibility across care settings. The company is also initiating its medical science liaison team to begin scientific engagement with potential customers.

Pipeline Partnerships and DPROT Development

Beyond INO-3107, Shea highlighted positive top-line phase III results announced by ApolloBio, Inovio’s Greater China partner for VGX-3100 in cervical dysplasia. According to Inovio, the study met its predefined primary efficacy endpoint of CIN 2 or CIN 3 lesion regression and HPV-16 and HPV-18 viral clearance, while demonstrating a favorable safety and tolerability profile.

ApolloBio plans to use the results to support a future regulatory filing for VGX-3100 in China. Inovio said the results support the potential for DNA medicines to address HPV-related diseases while reducing or eliminating the need for surgical intervention.

The company also presented preclinical research involving its DNA-encoded protein, or DPROT, platform targeting factor VIII production for hemophilia A at scientific conferences during the quarter. Inovio added Fabry disease and hypophosphatasia as rare-disease targets for the platform and said it is in discussions with potential partners to advance DPROT candidates.

Second-Quarter Financial Results and Cash Runway

Chief Financial Officer Peter Kies said Inovio ended the second quarter with $36.7 million in cash, cash equivalents and short-term investments, compared with $58.5 million at Dec. 31, 2025. In late July, the company completed an underwritten public offering that generated approximately $18.3 million in net proceeds.

• Second-quarter operating expenses declined 19% year over year to $18.6 million from $23.1 million.
• Operating expenses for the first six months of 2026 decreased 16% from the prior-year period.
• Net loss was $6 million, or $0.07 per share, compared with a net loss of $23.5 million, or $0.61 per share, a year earlier.
• The lower net loss included a $13.9 million non-cash gain from the fair-value adjustment of warrant liabilities.

Inovio estimated operational net cash burn of approximately $18 million for the third quarter and said its available resources, including the July offering proceeds, are expected to fund operations into late first quarter of 2027 and through a potential INO-3107 launch. Kies said that outlook includes expected pre-launch inventory-building and marketing costs during the fourth quarter and first quarter.

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source